AstraZeneca's IL-33-targeting antibody tozorakimab has hit the target in the third of three phase 3 trials in chronic ...

AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD). In ...

AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a ...

A new COPD drug, developed by Verona Pharma, was approved by the FDA Wednesday. The drug, ensifentrine, is the first new type of maintenance treatment for COPD in over a decade. In clinical trials, ...

Positive high-level results from the pivotal Phase III MIRANDA trial showed potential first-in-class tozorakimab demonstrated a statistically significant and clinically meaningful reduction in the ...

(NAPSI)—Chronic obstructive pulmonary disease (COPD) affects approximately 16 million Americans and can make even simple ...

GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for treating certain patients with chronic obstructive pulmonary disease (COPD), ...

NORTH PHILADELPHIA (WPVI) -- There's a potential new treatment for severe emphysema, and Philadelphia is a key test site for this small device with big potential to improve lives. In COPD (Chronic ...